Splenectomy Combined with Endoscopic Variceal Ligation (EVL) versus EVL Alone for Secondary Prophylaxis of Variceal Bleeding in Hepatosplenic Schistosomiasis: A Retrospective Case–Control Study

Jolivet Auguste Rakotomalala1, Chantelli Iamblaudiot Razafindrazoto1, Nitah Harivony Randriamifidy1, Behoavy Mahafaly Ralaizanaka3, Sonny Maherison2, Domoina Harivonjy Hasina Laingonirina3, Mialitiana Rakotomaharo3, Anjaramalala Sitraka Rasolonjatovo2, Mamisoa Anicet Rakotovao4,5, Andry Lalaina Rinâ Rakotozafindrabe4,5, Tovo Harimanana Rabenjahary4,5, Rija Fanantenantsoa4,5, Soloniaina Hélio Razafimahefa3, Rado Manitrala Ramanampamonjy2

1Hepato-Gastroenterology Unit, University Hospital Mahavoky Atsimo, Mahajanga, Madagascar; 2Gastroenterology Unit, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar; 3Hepato-Gastroenterology Unit, University Hospital Andrainjato, Fianarantsoa, Madagascar; 4General Surgery Unit, University Hospital Andrainjato, Fianarantsoa, Madagascar; 5Visceral Surgery Unit, University Hospital Tambohobe, Fianarantsoa, Madagascar

Correspondence: Chantelli Iamblaudiot Razafindrazoto, Gastroenterology Unit, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar, Email iamblaudiotchantelli@yahoo.com

Background: Hepatosplenic schistosomiasis (HSS) is one of the most common causes of portal hypertension in developing countries. Variceal bleeding is the most common cause of mortality during HSS. The objective of this study was to evaluate the efficacy of splenectomy associated with endoscopic variceal ligation (EVL) compared with EVL alone in preventing variceal bleeding in patients with HSS.

Methods: This was a single-center, retrospective, case–control study. Between January 2015 and December 2019, a total of 59 patients with HSS who had at least one variceal bleeding episode and received EVL with or without splenectomy were identified and stratified. In this case–control design, 22 patients had splenectomy + EVL (case group) and 37 patients had EVL alone (control group). The main endpoints were the rate of variceal rebleeding and the mortality rate between the two groups.

Results: The mean age of our patients was 39.92 ± 13.4 (19–75) years with a sex ratio of 1.8. The recurrence rate of variceal bleeding was significantly lower in the case group (splenectomy + EVL) than in the control group (EVL alone) (4.45% vs 27.2%, p = 0.041). There was no significant difference between the two groups in terms of mortality (4.54 vs 2.7%, p = 1.00).

Conclusion: Splenectomy combined with EVL was effective than EVL alone in preventing variceal rebleeding in patients with HSS.

Keywords: endoscopic variceal ligation, mortality, variceal bleeding, hepatosplenic schistosomiasis, splenectomy

Background

Schistosomiasis or bilharzia is the second most common parasitic endemic disease worldwide after malaria. It remains a global public health problem; it is endemic in 78 countries around the world, and of the 207 million people with schistosomiasis, 85% live in Africa, including Madagascar.1 In Madagascar, Schistosoma mansoni intestinal bilharzia, threatening 2.5 million people, of whom two million are infected. It is prevalent in the east, south and highlands of the country. Two to ten percent of patients infected with Schistosoma mansoni and Schistosoma japonicum develop the hepatosplenic form of the disease, which is characterized by perportal hepatic fibrosis, pre-sinusoidal portal hypertension and splenomegaly. Variceal bleeding is a major cause of morbidity and mortality in patients with non-cirrhotic portal
hypertension in developing countries. Hepatosplenic schistosomiasis (HSS) is complicated by variceal bleeding in 40% of cases with a mortality of 11% in the first episodes of bleeding. Secondary prevention of variceal bleeding in schistosomiasis-related portal hypertension does not present any particularities and calls upon the usual methods such as endoscopic variceal ligation (EVL) and non-selective betablockers. However, EVL still results in a similarly high rate of hemorrhagic recurrence, approximately 30%, and does not relieve portal hypertension and hypersplenism. Theoretically, the combination of splenectomy and EVL should correct not only portal hypertension but also hypersplenism, and thus prevent variceal bleeding. To our knowledge, there is no consensus to date on the secondary prevention of variceal bleeding in patients with HSS. This has been the subject of numerous studies based on different medical, endoscopic and surgical methods, including splenectomy associated with EVL. Recently, several case series indicate that combining surgical and endoscopic therapy may be more efficacious than using one technique alone. In fact, a retrospective study showed that endoscopic sclerotherapy was more effective in patients who had previously undergone surgical treatment for portal hypertension. The efficacy of combined surgical and endoscopic treatment in the secondary prevention of variceal bleeding in hepatosplenic schistosomiasis was reported in a recent Phase III randomized trial comparing sclerotherapy alone to sclerotherapy combined with surgery. The objective of this study was to evaluate the efficacy of the combination of EVL and splenectomy compared to EVL alone in the secondary prophylaxis of variceal bleeding in HSS patients in Madagascar.

Methods
Study Design, Participants, and Endpoints
This was a retrospective, single-center, case–control study conducted at the Gastroenterology Unit, University Hospital (UH) Joseph Raseta Befelatanana, Antananarivo, over a period of 5 years (60 months), from January 2015 to December 2019.

Our study concerned all patients with HSS, having at least one episode of variceal bleeding, treated by EVL with or without splenectomy. All patients meeting the following criteria were included in this study: having a diagnosis of HSS, having at least one episode of variceal bleeding and being managed by EVL. These patients were divided into 2 groups: the “Case” group included patients with splenectomy + EVL and the “Control” group included patients with EVL alone. The exclusion criteria were as follows: (a) HSS associated with cirrhosis of any cause or portal vein thrombosis, (b) HSS without variceal bleeding before EVL or before splenectomy.

The efficacy of each method was evaluated with respect to the rate of recurrence of variceal bleeding and the mortality rate.

Definitions
Hepatosplenic schistosomiasis diagnostic criteria were the following: (a) presence of splenomegaly, (b) presence of periportal fibrosis, (c) presence of radiological and/or endoscopic evidence of portal hypertension, and (d) positive schistosomiasis serology.

Esophageal varices were graded for size according to BAVENO VI: Grade 1 (Esophageal varices disappearing on insufflation), Grade 2 (Esophageal varices not disappearing on insufflation, nonconfluent), and Grade 3 (Esophageal varices not disappearing on insufflation, confluent).

Splenomegaly was classified according to Hackett’s criteria (WHO, 1963) into five categories ranging from 0 to 5: spleen not palpable, even in deep inspiration, was classified as 0, and spleen descending well below the umbilicus, exceeding the line passing between the umbilicus and the pubic symphysis was classified 5.

An episode of variceal bleeding was retained by the combination of several criteria: evidence of portal hypertension, presence of esophageal varices with red signs or recent upper gastrointestinal bleeding (hematemesis and/or melena).

Management of Variceal Bleeding Episodes and Description of Procedures (EVL and Splenectomy)
Patients with variceal bleeding (first episode or recurrence) were hospitalized and supportively cared according to a standardized protocol, and EVL sessions were scheduled every 4 weeks. A non-selective beta-blocker such as
propranolol was administered during hospitalization, in the absence of contraindications, at a starting dosage of 20 mg daily, increased every 3 days up to a total daily dose of 80–160 mg daily, to achieve the target heart rate (HR) between 55 and 60 beats/min or a decrease in HR of 25% from baseline HR. EVL was continued in all patients at 4-week intervals until eradication of esophageal varices. Splenectomy was performed in the Visceral Surgery Unit.

The indication for splenectomy in all patients in the splenectomy + EVL group was presence of significant splenomegaly associated with hypersplenism.

EVL consisted of the placement of rubber rings on variceal columns, which are sucked into a plastic hollow cylinder attached to the tip of the endoscope by an experienced senior endoscopist. Ligation was started at the lower end of the esophagus and proceeded upward in a spiral fashion. Splenectomy was performed open by an experienced senior surgeon but without esophagogastric devascularization.

Statistical Analysis
The data were recorded in predesigned formats and were statistically analyzed using Statistical Package for Social Sciences (SPSS) version 16 software. Data were expressed as mean ± standard deviation (SD) and number (percent) for nominal data. Comparisons between two groups were performed using Student’s t-test for parametric data and the Mann–Whitney test for nonparametric data. The chi-square ($\chi^2$) test and Fisher exact test were applied for analysis of categorical data. All P-values are two-tailed, with values <0.05 considered statistically significant.

Results
Characteristics of Study Population
During the study period, 68 patients had HSS, with at least one episode of variceal bleeding, treated by EVL with or without splenectomy. Fifty-nine patients were selected, including 22 patients in the case group (EVL + splenectomy) and 37 patients in the control group (EVL alone). Nine patients were excluded: 3 patients had a combination of HSS and cirrhosis, and 6 patients had unworkable records. The flow-chart of the study showed in Figure 1. The two groups are probably not similar in terms of severity of portal hypertension because the mean number of previous bleeding episodes was higher in the case group compared with the control group (3.25 ± 3.07 vs 2.24 ± 1.52, $p = 0.003$). All other characteristics of our study population were similar in both groups. The demographic and clinical characteristics of patients between the two groups are shown in Table 1.

Figure 1 Flowchart of study.
Treatment Outcomes

The rate of variceal bleeding recurrence was significantly lower in the case group (EVL + splenectomy) than the control group (EVL alone) (4.45% vs 27.2%, \( p = 0.041 \)). There was no significant difference between the two groups in terms of mortality (1/22 vs 1/37, \( p = 1.00 \)) (Table 2). One 22-year-old patient in the case group died of bacterial pneumonia with severe sepsis and one 59-year-old patient in the control group died of variceal bleeding with shock.

Discussion

We conducted a retrospective case–control study in patients with HSS who presented with variceal bleeding and were managed in the Gastroenterology Unit, UH Joseph Raseta Befelatanana, Antananarivo. The objective of this study was to evaluate the efficacy of EVL associated with splenectomy compared to EVL alone in the context of secondary prevention of variceal bleeding.

To our knowledge, this was the first Malagasy study comparing these two therapeutic methods, which is the main focus of our study.

The seriousness of HSS lies in the risk of variceal bleeding episodes which could be fatal in the absence of adequate emergency management. The prevention of recurrent bleeding is a crucial element to decrease the risk of morbidity and mortality related to this pathology. Indeed, HSS is a state of circulatory hyperdynamia that is due to the formation of portosystemic shunts secondary to portal hypertension. \(^1^1\) Portal hypertension may also be responsible for hyperplasia of the reticuloendothelial system and chronic venous congestion leading to splenomegaly and its complications, notably hypersplenism. \(^1^2\) On the other hand, hypersplenism can induce an increase in splenic vein blood flow leading to an increase in the rate of variceal bleeding.

### Table 1 Baseline Characteristic of Patients

<table>
<thead>
<tr>
<th>Variables</th>
<th>Splenectomy + EVL Group (n=22)</th>
<th>EVL Only Group (n=37)</th>
<th>( P )-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender, Male/Female, n (%)</td>
<td>12 (54.5)/10 (45.5)</td>
<td>26 (70.27)/11 (29.73)</td>
<td>0.22</td>
</tr>
<tr>
<td>Mean age ± SD (years)</td>
<td>37.5 ± 13.04</td>
<td>41.36 ± 13.59</td>
<td>0.98</td>
</tr>
<tr>
<td>Ethanol, n (%)</td>
<td>1 (4.55)</td>
<td>3 (8.11)</td>
<td>0.06</td>
</tr>
<tr>
<td>Smoking, n (%)</td>
<td>0 (0.00)</td>
<td>3 (8.11)</td>
<td></td>
</tr>
<tr>
<td>Ethanol + smoking, n (%)</td>
<td>0 (0.00)</td>
<td>6 (16.22)</td>
<td></td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>2 (10.52)</td>
<td>5 (12.9)</td>
<td>0.7</td>
</tr>
<tr>
<td>Co-infection with HBV, n (%)</td>
<td>2 (9.09)</td>
<td>3 (9.11)</td>
<td>0.49</td>
</tr>
<tr>
<td>Co-infection with HCV, n (%)</td>
<td>1 (4.55)</td>
<td>0 (0.00)</td>
<td></td>
</tr>
<tr>
<td>Hepatomegaly, n (%)</td>
<td>1 (4.55)</td>
<td>7 (19.92)</td>
<td>0.23</td>
</tr>
<tr>
<td>Ascites, n (%)</td>
<td>4 (18.18)</td>
<td>6 (16.22)</td>
<td>0.61</td>
</tr>
<tr>
<td>Number of previous bleeding episodes, mean ± SD</td>
<td>3.25 ± 3.07</td>
<td>2.24 ±1.52</td>
<td>0.003</td>
</tr>
<tr>
<td>Grade of varix ± red signs, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 3 without red signs</td>
<td>2 (9.09)</td>
<td>12 (32.43)</td>
<td>0.15</td>
</tr>
<tr>
<td>Grade 3 with red signs</td>
<td>13 (59.09)</td>
<td>18 (48.65)</td>
<td></td>
</tr>
<tr>
<td>Grade 3 + GOV</td>
<td>6 (27.27)</td>
<td>6 (16.21)</td>
<td></td>
</tr>
<tr>
<td>Grade 2</td>
<td>1 (4.55)</td>
<td>1 (2.70)</td>
<td></td>
</tr>
<tr>
<td>Number of EVL sessions, mean ± SD</td>
<td>2.41±1.05</td>
<td>2.35±1.03</td>
<td>0.89</td>
</tr>
<tr>
<td>Propranolol dose per day, 80mg/160mg</td>
<td>11/11</td>
<td>12/25</td>
<td>0.27</td>
</tr>
</tbody>
</table>

**Abbreviations:** EVL, endoscopic variceal ligation; SD, standard deviation; HBV, hepatitis B virus; HCV, hepatitis C virus; GOV, gastroesophageal varices.

### Table 2 Hemorrhagic Recurrence and Death Occurrence

<table>
<thead>
<tr>
<th>Variables</th>
<th>Splenectomy + EVL Group (n=22)</th>
<th>EVL Only Group (n=37)</th>
<th>( P )-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemorrhagic recurrence (variceal rebleeding), n (%)</td>
<td>1 (4.55)</td>
<td>10 (27.02)</td>
<td>0.04</td>
</tr>
<tr>
<td>Death occurrence, n (%)</td>
<td>1 (4.55)</td>
<td>1 (2.70)</td>
<td>1.00</td>
</tr>
</tbody>
</table>

**Abbreviation:** EVL, endoscopic variceal ligation.
increase in portal blood flow and thus, can maintain this state of circulatory hyperdynamia.13,14 We suggested that hypersplenism was one of the factors in persistent portal hypertension even after eradication of esophageal varices. Thus, splenectomy might be justified in the management of noncirrhotic portal hypertension by correcting hypersplenism and thereby decreasing portal blood flow.3,14,15 In contrast to cirrhosis, there is still no consensus regarding the prevention of hemorrhagic recurrence in patients with HSS because of the lack of sufficient literature data. However, studies have suggested a combination of surgical (splenectomy) and endoscopic methods to prevent recurrent bleeding.9,16–18

In this study, the rate of hemorrhagic recurrence in the splenectomy + EVL group was significantly lower than in the EVL alone group (4.54% vs 27%, p = 0.041). These results differed from those of Jiang et al who found no significant difference in the rate of hemorrhagic recurrence between the two groups at 5 years (44.2% vs 52.3%, p = 0.449).16 On the other hand, a Brazilian phase III randomized clinical trial comparing 25 patients with endoscopic treatment alone and 22 patients with combined splenectomy and endoscopic treatment found a significantly lower rate of variceal bleeding recurrence in patients treated with combined splenectomy and endoscopic treatment compared to those treated with endoscopic treatment alone (9.1% vs 36.2%, p = 0.029).9

In our study, EVL was used as an endoscopic method to eradicate esophageal varices. According to the study by Siqueira et al, there was no difference between sclerotherapy and EVL in terms of efficacy for the management of esophageal varices on HSS.19 However, sclerotherapy is currently no longer recommended for the management of esophageal varices regardless of their cause.10 In our study, esophagogastric devascularization was not performed because of the complexity of this procedure, which may prolong the operative time during splenectomy. In the literature, various studies have shown a significant reduction in the intravascular pressure of esophageal varices in patients managed by splenectomy associated with esophagogastric devascularization.7,20,21 The combination of splenectomy and esophagogastric devascularization could also result in a significant decrease in the frequency of risk factors for recurrent bleeding, including the size of the varices, the presence of red signs, and the presence of portal hypertensive gastropathy.7 However, the eradication rate of esophageal varices related to the association of splenectomy and esophagogastric devascularization is 18.2% but this could increase up to 86%, when it is coupled with an endoscopic method.22,23 In this case, it could prevent hemorrhagic recurrence in 82.5% of cases over a period of 20 years after surgery.8

In terms of mortality, this study showed no significant difference between the two groups (4.54% vs 2.7%; p = 1.00). Two groups are probably not similar in terms of severity of portal hypertension. This is illustrated by the fact that the splenectomy group had a significantly higher number of prior bleeding episodes (3.25 versus 2.24, p < 0.001). This could explain the lack of survival benefit. These results were different from those reported in the Chinese study which found a significant difference between the two groups with a lower 5-year mortality rate in the EVL + splenectomy group (17.3% vs 46.8%; p = 0.037).16 Lacet et al reported a mortality rate of 4% in patients managed by endoscopy alone.9 A Brazilian study found a mortality rate of 4.5% after 20 years of evolution after the combined method (surgical and endoscopic).8 An African study reported that the one-year survival rate in patients treated with EVL + splenectomy was 97.3%.17

**Limitations of the Study**

The major limitation of the study was that the allocation to each group was at the discretion of the treating physician and the two groups are probably not similar in terms of severity of portal hypertension. This is illustrated by the fact that the splenectomy group had a significantly higher number of prior bleeding episodes (3.25 versus 2.24, p < 0.001). This could explain the lack of survival benefit and may have underestimated the differences in rebleeding rates between the two groups. The retrospective and monocentric nature of the study constituted additional limitations of the study inducing a bias in our research. Other associated factors that could influence prognosis were not studied and long-term follow-up could not be performed. The presence of selection bias remains possible in patients who underwent splenectomy + EVL.

**Conclusion**

EVL associated with splenectomy is more effective than EVL alone in reducing the risk of recurrence of variceal bleeding in patients with HSS. Because of the lack of current recommendations or consensus on the management of HSS,
spleenectomy combined with EVL may be a feasible method to prevent recurrence of variceal bleeding. However, our study is inconclusive in predicting the risk of mortality associated with each method. Thus, a new prospective, multi-center, long-term study is needed to indicate this therapeutic method for the prevention of morbidity and mortality related to complications of HSS.

**Data Sharing Statement**
Data supporting the conclusions of this study are available from the corresponding author on reasonable request.

**Ethical Considerations**
This study was ethically and scientifically approved by ethic committee of University Hospital Joseph Raseta Befelatanana, with a waiver for informed consent as all patients were de-identified. All study procedures were conducted in accordance with the Declaration of Helsinki. All authors had access to the study data and reviewed and approved the final manuscript before submission.

**Acknowledgments**
The authors would like to thank the members of the Gastroenterology Unit of the Joseph Raseta Befelatanana University Hospital, Visceral Surgery Unit, UH Joseph Ravoahangy Andrianavalona, Antananarivo, and Visceral Surgery Unit, UH Tambohobe, Fianarantsoa, Madagascar.

**Author Contributions**
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

**Disclosure**
The authors declare that they have no conflicts of interest in relation to this work.

**References**


